Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IA-14069 in Healthy Subjects, With an Extension to Explore Any Drug-Drug Interaction Potential With Methotrexate (Part 1), and in Patients With Rheumatoid Arthritis, With Preliminary Assessment of Efficacy in Patients (Part 2)
Latest Information Update: 27 May 2025
At a glance
- Drugs IA-14069 (Primary) ; Methotrexate (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors iLab
Most Recent Events
- 20 May 2025 Planned End Date changed from 1 Dec 2024 to 1 Feb 2026.
- 20 May 2025 Planned primary completion date changed from 1 Sep 2024 to 1 Nov 2025.
- 11 Oct 2023 Planned End Date changed from 1 Nov 2023 to 1 Dec 2024.